Four Oral Chinese Patent Medicines for Treatment of Functional Dyspepsia： A Rapid Health Technology Assessment
10.13422/j.cnki.syfjx.20222095
- VernacularTitle:4种消导类口服中成药治疗功能性消化不良的快速卫生技术评估
- Author:
Miaomiao LI
1
;
Hui ZHAO
2
;
Zeqi DAI
1
;
Xue WU
1
;
Simin XU
1
;
Xudong TANG
3
;
Xing LIAO
1
Author Information
1. Center for Evidence-based Chinese Medicine，Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences，Beijing 100700，China
2. China Center for Evidence-based Traditional Chinese Medicine，Beijing 100700，China
3. China Academy of Chinese Medical Sciences，Beijing 100700，China
- Publication Type:Journal Article
- Keywords:
functional dyspepsia;
Chinese patent medicines;
comprehensive clinical evaluation;
rapid health technology assessment;
Simotang oral liquid
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(20):161-169
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the safety， efficacy， and economy of the four Chinese patent medicines （CPMs）， including Simotang oral liquid， Liuwei Anxiao capsule， Baohe pill， and Jianwei Xiaoshi oral liquid in the treatment of functional dyspepsia （FD） by a rapid health technology assessment （RHTA）， thus providing evidence support for clinical decision making. MethodChina National Knowledge Infrastructure （CNKI）， WanFang Database， VIP Chinese Technology Periodical Database （VIP）， China Biology Medicine disc （CBMdisc）， PubMed， EMBASE， Cochrane Library， and Web of Science were searched by computer from inception to March 2022. After literature screening， data extraction， and quality evaluation， the descriptive analysis of the results combined with visual charts was performed. Nineteen studies were included， involving 18 randomized controlled trials （RCTs） and 1 Meta-analysis. Neither economic studies nor health technology assessment （HTA） reports were retrieved. ResultThe four CPMs were safe and effective in the treatment of FD， but economic research was lacking. Among them， Simotang oral liquid could be used for children with FD and FD caused by qi and food stagnation， liver and spleen disharmony， and liver and spleen stagnation. Liuwei Anxiao capsule could be used for adult patients with FD caused by food stagnation. Baohe pill could be used for the elderly with FD. Jianwei Xiaoshi oral liquid could be used for children with FD caused by spleen and stomach weakness. ConclusionThe four CPMs have their advantages in the treatment of FD. Among them， the clinical universality of Simotang oral liquid is higher. However， the quality of clinical evidence is generally low， and comparative analysis among drug dosage forms is lacking. In the future， it is necessary to improve， apply， and promote RHTA for rapid evidence production while carrying out a more standardized and scientific evidence-based demonstration of the comprehensive clinical efficacy of CPMs.
